Most importantly, these in vitro findings were further supported with data from The Cancer Genome Atlas (TCGA), which shows that TIGAR is amplified in different cancer types including ovarian cancer, and higher expression of TIGAR is associated with poor overall survival of patients with high-grade serous ovarian cancer. The gene discussed is TIGAR; the disease is ovarian serous adenocarcinoma.